TNFRSF17人重组蛋白

蛋白名称:TNFRSF17人重组蛋白，10620-H86H-SP

蛋白构建:A DNA sequence encoding the extracellular domain (Met1-Ala54) of human TNFRSF17 (NP_001183.2) was expressed with a C-terminal polyhistidine tag. The protein is site-specifically conjugated with AF 488 (Excitation = 495-566 nm, Emission Max.= 575 nm).

表达宿主:HEK293 Cells

蛋白纯度:

蛋白活性:

1.Flow cytometric analysis of anti-BCMA CAR expression. 5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:125 dilution of PE-conjugated human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP) and negative control protein. Non-transduced 293 cells were used as a control (left). PE signal was used to evaluate the binding activity (QC tested).

2.Binding activity of PE-conjugated BCMA protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and PE-conjugated human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. PE signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

3.Flow cytometric analysis of anti-BCMA CAR expression. HEK293 cells were lentivirally transduced with anti-BCMA CAR. Non-transduced HEK293 cells were used as a control (shown on the left). 2 μL (1 test) of site-specifically PE-conjugated human BCMA protein from two vendors (competitor A and SINO) was used. The results demonstrated that SINO’s 10620-H86H-SP has a much higher fluorescence intensity than that of the competitor (Routinely tested).

4.Flow cytometric analysis using PE conjugated BCMA protein. 5e5 of anti-BCMA CAR-293 cells were stained with PE-conjugated human BCMA protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP). Non-transduced 293 cells were used as a control (Black Histogram).  The protein exhibited stable performance after multiple freeze-thaw cycles (5, 10 cycles)

蛋白内毒素:< 1.0 EU per μg protein as determined by the LAL method.

预测N端:Met 1

蛋白分子量:The protein has a predicted molecular mass of 11.8 kDa.

蛋白NP号:NP_001183.2

蛋白氨基酸序列:Met1-Ala54

蛋白标签:C-His

欢迎去义翘神州网查看TNFRSF17人重组蛋白，10620-H86H-SP详细信息。网址：https://cn.sinobiological.com/recombinant-proteins/human-bcma-10620-h86h-sp

义翘神州研发团队拥有多年的重组蛋白研发经验。多年来，我们的团队已开发出超过9300余种重组蛋白，涵盖免疫检查点、抗体药物靶点、CAR-T细胞治疗靶点、Fc受体、流感病毒蛋白以及细胞因子等热门研究领域。义翘神州重组蛋白具有高纯度、高生物活性和低内毒素水平等特性，可为生物药靶点发现、蛋白质结构和功能分析、细胞疗法和重组酶酶学性质等科学研究提供支持。

义翘神州利用蛋白表达平台，提供重组蛋白生产"一站式"技术服务。我们的服务包括蛋白基因合成、蛋白质密码子优化、蛋白质表达载体设计、大规模细胞培养和发酵、蛋白纯化和蛋白质量控制检测。我们在蛋白表达和大规模生产方面有着显著的成本节约和速度优势，同时在设计各种类型的重组蛋白纯化项目（带或不带纯化标签）方面也拥有着丰富的经验和专业技术。 义翘神州拥有经验丰富的技术团队，每年可研发生产1,000+种重组蛋白开发和大规模生产项目。我们有能力进行快速的蛋白质表达和纯化工艺开发，根据需求进行工艺放大研究，并且可满足高通量和大规模批量生产蛋白质的要求。 我们致力于成为重组蛋白和单克隆抗体大规模生产的实验室，为药物研发企业和生命科学机构提供高水平的技术服务。

欢迎小伙伴来咨询哦!  请注明来源、姓名，单位！

关注义翘神州或添加微信“sinobio2023"进行联系！